NOBILIS THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nobilistx.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Xenon Inhalation for Treatment of Panic Disorder
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Nobilis Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04432155
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Nobilis Therapeutics Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04097080
- Locations
- 🇷🇺
Institute of Addictology, Moscow, Russian Federation
🇷🇺MONIKI, Moscow, Russian Federation
Xenon Inhalation for Treatment of Posttraumatic Stress Disorder
Phase 2
- Conditions
- Post Traumatic Stress Disorder
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Nobilis Therapeutics Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03635827
News
No news found